IL-10 constrains sphingolipid metabolism via fatty acid desaturation to limit inflammation

Autumn G. York, Mathias Skadow, Rihao Qu, Joonseok Oh, Walter K. Mowel, J. Richard Brewer, Eleanna Kaffe, Kevin J. Williams, Yuval Kluger, Jason M. Crawford, Stephen T. Smale, Steven J. Bensinger, Richard A. FlavellbioRxiv 2023 · DOI

TL;DR

This study reveals a novel mechanism by which the anti-inflammatory cytokine IL-10 controls inflammation: by regulating sphingolipid metabolism. Specifically, IL-10 promotes the synthesis of monounsaturated fatty acids (MUFAs), which in turn limits the production of pro-inflammatory saturated very long-chain ceramides. This discovery opens avenues for new therapeutic strategies targeting metabolic pathways to combat chronic inflammation.

What Problem Does This Paper Address?

Chronic inflammation is a root cause of numerous diseases, from inflammatory bowel disease to neurodegeneration. While IL-10 is a known anti-inflammatory cytokine that dampens immune cell responses, the precise molecular mechanisms by which it achieves this have remained elusive. The authors sought to understand how IL-10 signaling ultimately suppresses inflammation, hypothesizing that it might involve rewiring lipid metabolic programs within immune cells.

Methods

The researchers employed a multi-faceted approach:

  • Lipidomics: Unbiased shotgun lipidomic analysis was used to comprehensively profile lipid species in macrophages, identifying changes in ceramides and other lipids.
  • Genetic Manipulation: They utilized knockout (KO) models, specifically deleting genes like CerS2 (involved in ceramide synthesis) and IL-10R (the IL-10 receptor), as well as creating double KO mice (IL10R/CerS2 DKO).
  • Cellular Assays: Macrophages were stimulated with TLR ligands (like Pam3CysK4) and treated with various lipid species (ceramides, MUFAs) to assess inflammatory gene expression via qPCR.
  • In Vivo Models: Bone marrow chimeras were generated to study the role of IL-10 and CerS2 in colonic inflammation. They also used a DSS-induced colitis model in mice.
  • Metabolic Tracing: Stable-isotope tracer analysis (using ¹³C-glucose) was employed to track de novo fatty acid synthesis.
  • Single-cell RNA Sequencing (scRNAseq): This technique was used to analyze macrophage populations in the colon lamina propria, providing a high-resolution view of cellular heterogeneity and gene expression.

Datasets

The study generated and analyzed several datasets:

  • Lipidomic data: From WT and IL-10 KO bone marrow-derived macrophages (BMDMs) under various conditions (naïve, TLR2-activated).
  • RNAseq data: From WT and IL-10 KO BMDMs, matched to lipidomics samples, to analyze gene expression related to sphingolipid metabolism.
  • scRNAseq data: From colonic lamina propria immune cells of chimeric mice (IL-10R KO vs. IL-10R/CerS2 DKO), focusing on macrophage populations.
  • qPCR data: Quantifying the expression of inflammatory genes (e.g., Cxcl1, Il6, Il1b, Il12b) in various experimental conditions.
  • ELISA data: Measuring lipocalin levels in feces as a marker of colonic inflammation.

No new benchmarks were introduced; the study focused on analyzing existing biological systems and molecular pathways.

Key Insights and Ideas

  • IL-10's Anti-inflammatory Action is Lipid-Mediated: The most significant finding is that IL-10 doesn't just broadly suppress immune signaling; it actively reshapes lipid metabolism to achieve this. This shifts the understanding of IL-10's function beyond direct cytokine receptor signaling.
  • Saturated VLC Ceramides Drive Inflammation: The study pinpoints saturated very long-chain (VLC) ceramides as key culprits in driving the exacerbated inflammation seen in IL-10 deficient macrophages. This is a crucial insight into the specific lipid species involved.
  • MUFA Synthesis is the Key Regulator: Surprisingly, the regulation of these pro-inflammatory ceramides is linked to the synthesis of monounsaturated fatty acids (MUFAs). IL-10 promotes MUFA synthesis, which in turn limits saturated ceramide production. This highlights a critical metabolic feedback loop.
  • "Metabolic Correction" as a Therapeutic Strategy: The ability of exogenous MUFAs to reduce inflammation in IL-10 deficient settings suggests that manipulating lipid metabolism could be a viable therapeutic approach for inflammatory diseases.

Key Results

  • IL-10 Deficiency Leads to Increased Saturated VLC Ceramides: Macrophages lacking IL-10 showed significantly higher levels of saturated VLC ceramides, which correlated with heightened inflammatory gene expression.
  • CerS2 Deletion Mitigates Inflammation: Genetic deletion of CerS2, an enzyme essential for VLC ceramide production, reduced the exacerbated inflammatory gene expression in IL-10 deficient macrophages, both in vitro and in vivo.
  • MUFA Supplementation Reduces Inflammation: Adding exogenous MUFAs (like oleic acid, 18:1) to IL-10 deficient macrophages significantly reduced inflammatory gene expression, while saturated or poly-unsaturated fatty acids did not.
  • SCD2 Deficiency Mimics IL-10 Deficiency: Myeloid-specific deletion of Scd2 (an enzyme involved in MUFA synthesis) led to increased ceramides and inflammatory gene expression, similar to IL-10 deficiency.
  • MUFA Gavage Reduces Colonic Inflammation: In mouse models of colonic inflammation, oral gavage of MUFAs (24:1 or 18:1) significantly reduced fecal lipocalin (a marker of inflammation) and immune cell infiltration.

Limitations and Future Work

  • Transcriptional Regulation: The study found that IL-10's influence on sphingolipid metabolism was not mediated at the transcriptional level of pathway enzymes, suggesting post-transcriptional or allosteric regulation. Further biochemical analysis is needed to fully delineate how MUFAs impact ceramide de novo synthesis.
  • SM Degradation vs. Synthesis: The observed reduction in saturated and mono-unsaturated sphingomyelins (SMs) in IL-10 signaling loss could be due to perturbed ER-to-Golgi transport or enhanced SM degradation. The exact mechanism for SM degradation's impact on inflammation remains unclear.
  • VLC Ceramide Tail "Desaturation Status": The authors suggest future studies should focus on how saturated versus unsaturated VLC ceramides specifically mediate inflammatory gene expression.
  • Therapeutic Potential: While promising, the findings suggest that dietary intervention with MUFA-rich foods (like the Mediterranean diet) might be beneficial for IBD patients lacking functional IL-10 signaling. Further research into "fatty acid metabolite correction" as a treatment is warranted.

Summary updated

Abstract

Abstract Unchecked chronic inflammation is the underlying cause of many diseases, ranging from inflammatory bowel disease to obesity and neurodegeneration. Given the deleterious nature of unregulated inflammation, it is not surprising that cells have acquired a diverse arsenal of tactics to limit inflammation. IL-10 is a key anti-inflammatory cytokine that can limit immune cell activation and cytokine production in innate immune cell types; however, the exact mechanism by which IL-10 signaling subdues inflammation remains unclear. Here, we find that IL-10 signaling constrains sphingolipid metabolism. Specifically, we find increased saturated very long chain (VLC) ceramides are critical for the heightened inflammatory gene expression that is a hallmark of IL-10-deficient macrophages. Genetic deletion of CerS2, the enzyme responsible for VLC ceramide production, limited exacerbated inflammatory gene expression associated with IL-10 deficiency both in vitro and in vivo , indicating that “metabolic correction” is able to reduce inflammation in the absence of IL-10. Surprisingly, accumulation of saturated VLC ceramides was regulated by flux through the de novo mono-unsaturated fatty acid (MUFA) synthesis pathway, where addition of exogenous MUFAs could limit both saturated VLC ceramide production and inflammatory gene expression in the absence of IL-10 signaling. Together, these studies mechanistically define how IL-10 signaling manipulates fatty acid metabolism as part of its molecular anti-inflammatory strategy and could lead to novel and inexpensive approaches to regulate aberrant inflammation.
BibTeX
@misc{york2023il,
  author = {Autumn G. York and Mathias Skadow and Rihao Qu and Joonseok Oh and Walter K. Mowel and J. Richard Brewer and Eleanna Kaffe and Kevin J. Williams and Yuval Kluger and Jason M. Crawford and Stephen T. Smale and Steven J. Bensinger and Richard A. Flavell},
  title = {{IL-10 constrains sphingolipid metabolism via fatty acid desaturation to limit inflammation}},
  year = {2023},
  doi = {10.1101/2023.05.07.539780},
  howpublished = {bioRxiv},
}
Figure